8:01AM Sinovac Biotech receives GMP certification for mumps vaccine production facility; On track to commence commercial production in Q3 2012 (SVA) 2.25 : Co announced today that it has received GMP certification from the China State Food and Drug Administration (SFDA) for the Company's dedicated mumps vaccine production plant at its Sinovac Dalian facility. The SFDA issued a public announcement on September 12, 2012, stating that the Good Manufacturing Practices certification was issued to Sinovac with the certificate number CN20120080.
The SFDA issued a public notification in July 2012 stating that Sinovac Dalian's mumps vaccine production plant is in compliance with the new GMP guidelines (2010 version) following the site inspection and documentation review. The Co obtained the production license from the SFDA for its mumps vaccine in Dec 2011. Sinovac continues to anticipate that it will be in a position to commence commercial production of the mumps vaccine in Q3 2012 and is on track to launch the mumps vaccine in China following the batch release process
Market Data 
Markets 
AI
